Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response
Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease
Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival
Volasertib Shows Response In 31 Percent of Acute Myeloid Leukemia Patients
Breast Cancer Risk Increases With Repeated CT Imaging
Scatter Radiation from Mammography Presents No Increased Cancer Risk
MRI, 3D Ultrasound Combination Can Guide Prostate Biopsies
Perifosine, Sorafenib Combination Well Tolerated in Several Lymphomas
NCI-Approved CTEP Trials For the Month of December
FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer
Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- In the Headlines: MD Anderson’s Pisters on doing “something gigantic for pediatric cancer”
- At House hearing, Democrats clash with RFK Jr. over “radical obstruction of congressional oversight,” vaccine policies
Rep. Lori Trahan: “People are going to die” - As cancer patients use AI chatbots, dangers lurk—but new safeguards can help
